Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfofI5{Oi53IN88US=> MofsNU01KGR? MUXEUXNQ NV3tVINJ\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NGfoPGEzPTR7MEO4Ny=>
H1703 NX\IPG5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0eHc3Oi53IN88US=> NXroTotTOS12IHS= NVq0NYhYTE2VTx?= MnL3[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MYeyOVQ6ODN6Mx?=
HUVECs Mn\ER5l1d3SxeHnjbZR6KEG|c3H5 MnH3NVAxKG6P NEXtNFAzPCCq MmrxZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NF3PWYkzPTR3MEG4Oi=>
APRE-19 MYjBdI9xfG:|aYOgRZN{[Xl? NILH[JE2KM7:TR?= M164flI1KGh? NHXERVNi[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MVWyOVMzQTZzNx?=
MDA-MB-231 NWf6NZpYSXCxcITvd4l{KEG|c3H5 NXXC[3J6OcLizszNxsA> M4DMdlQ5KGh? NE\XbVdFVVOR M{nCZ4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg NWGwVnY3OjV|MEC5N|I>
MCF7 M13TdWZ2dmO2aX;uJGF{e2G7 MkLnNVAxKG6P M{\XblI1KGh? MVrlcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> M{PTfFI2OTd{NUW3
HT-29  Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxMlXDqML3TR?= NFjzSI46PiCq NFLZNoJl\WO{ZXHz[ZMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIlvcGmkaYTl[EBjgSCNWV7B NVTt[pJ1OjVyMUKxNlM>
MO59K  MY\DfZRwfG:6aXPpeJkhSXO|YYm= M3:zZ|XDqM7:TR?= M{jnRVch\A>? Ml;jSG1UVw>? NIrlbnZmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= M2HTZVI1QTV|NU[x
MO59J NHjCVWhEgXSxdH;4bYNqfHliQYPzZZk> MXy1xsDPxE1? MkPHO{Bl MX3EUXNQ NHrlVJlmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= MXqyOFk2OzV4MR?=
MO59K  M2\3OmFxd3C2b4Ppd{BCe3OjeR?= MYSxNEDPxE1? MojHNlQhcA>? NETmc2ZFVVOR NYjvRYhKcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M3Tn[FI1QTV|NU[x
MO59J MV3BdI9xfG:|aYOgRZN{[Xl? NFSxTnoyOCEQvF2= MoLPNlQhcA>? MoPNSG1UVw>? MnHkbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv M2PtVFI1QTV|NU[x
HepG2 Mkm4SpVv[3Srb36gRZN{[Xl? M4PCc|ExOCCwTR?= MormNE42KGh? MlT4SG1UVw>? NXzoZYVI[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NUHmdo9POjR6NkOzOVA>
A549  MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnPe|A{KML3TdMg NFWycmszKGh? M324SpN2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? NH75dmgzPDh2N{i2Ny=>
A549  MUHGeY5kfGmxbjDBd5NigQ>? M1ryS|ExyqEQvH5CpC=> NXjvWpY4OTZiaB?= M1\NdWROW09? NVvpeHRIdW:mdXzheIV{KHSqZTDJRXYhemWybHnjZZRqd25iYX7kJINifXOnczDy[ZRmdnSrb36gc4YhVlBiaX6geIhmKG63Y3zleZMv NVnBRWRYOjR6MEKxNVE>
SK-N-LO MoP4SpVv[3Srb36gRZN{[Xl? MWWxNFAhdk1? NICwUokxNjViaB?= MkK0[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v MYOyOFY2PDZyNh?=
HL-60 NHmzUHRHfW6ldHnvckBCe3OjeR?= MWOwMlHDqM7:TR?= M4\qWVczKGh? MW\icI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= M4TEflI1PjB5Mkez
HepG2  M3HSb2Z2dmO2aX;uJGF{e2G7 NFPmTm4zODBibl2= NXjWVWFjOC53IHi= NVe5UXpX[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= M1HrdFI1PTN3MUmy
H520 MnnMSpVv[3Srb36gRZN{[Xl? NHzjdGYyOMLizszN M{L4ZVEhcA>? MUTEUXNQ MoLm[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NFXoUW0zPDR2N{mzOS=>
H1975 M2TlZmZ2dmO2aX;uJGF{e2G7 MlnsNVDDqM7:TR?= NGnCZpYyKGh? MWjEUXNQ M4T1[4Rm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NE\FOYkzPDR2N{mzOS=>
MG-63 MmXDRZBweHSxc3nzJGF{e2G7 NYrK[2FpOTBiwsXN MXmxNkBp NGjGU5ZmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? M4\ZZlI1OzV6M{Cx
5637 NHy5eVhCeG:ydH;zbZMhSXO|YYm= Ml\LNVDDqM7:TR?= MlXSOFAhdWmw MoT0doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv M2XZdVI1OzN|OE[4
HEK-293 M2K3WmZ2dmO2aX;uJGF{e2G7 NH;rb5EyPTCwTR?= M3HsOVE3KGh? MojZSG1UVw>? M{jiNoRm[3KnYYPld{BEWlRiYXP0bZZqfHl? M3LueVI1OzJ2M{[2
SW480  M2DsWGZ2dmO2aX;uJGF{e2G7 M1;lblE2OG6P MnHENlAhcA>? MlzGSG1UVw>? MkLKdoVlfWOnczDj[YxtfWyjcjDhZ4N2dXWuYYTpc44hd2ZizsKtZ4F1\W6rbh?= MYiyOFMzPDN4Nh?=
HepG2 NFTITXBHfW6ldHnvckBCe3OjeR?= MYixNFAhdk1? M12wUlI1KGh? NXnye|hF[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= M3fsWlI1Ojl5NUGw
HCT 116  NXr0WHhiTnWwY4Tpc44hSXO|YYm= MknNNVAxKG6P Mn7NNlQhcA>? MV3heJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MUiyOFI6PzVzMB?=
BEL/FU MXjGeY5kfGmxbjDBd5NigQ>? NXHPXFZ3OSCvTR?= M1\HSVI1KGh? MWPk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> NXjCWoltOjR{M{KwPVk>
Huh7  MVXGeY5kfGmxbjDBd5NigQ>? NGGzOWE{yqEQvF2= MWWxJIg> NV3hbGFHemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? NVfiZVd{OjRzOESxPVY>
A-375 M1j1NWFxd3C2b4Ppd{BCe3OjeR?= MkP6OE85KM7:TR?= NELXRVczPCCq NX;lbZhx\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M{\4RlI1OTF|MUez
A-375-TS  MoXLRZBweHSxc3nzJGF{e2G7 M{DOeVQwQCEQvF2= M2T3blI1KGh? MUHlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MX6yOFEyOzF5Mx?=
Mel-HO NH3qe5FCeG:ydH;zbZMhSXO|YYm= M1Kz[VQwQCEQvF2= MnfnNlQhcA>? Mojw[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NUfvRnRPOjRzMUOxO|M>
Mel-HO-TS MY\BdI9xfG:|aYOgRZN{[Xl? NEfaVZk1NzhizszN MnjqNlQhcA>? NVvFXW1F\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NGLhVWozPDFzM{G3Ny=>
MeWo NF\GTpRCeG:ydH;zbZMhSXO|YYm= MlntOE85KM7:TR?= MVKyOEBp NF24XlVmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NV\q[lJuOjRzMUOxO|M>
Mel-2a MYrBdI9xfG:|aYOgRZN{[Xl? M1\Z[VQwQCEQvF2= NEnVS2kzPCCq M{X2bYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NEnPcpEzPDFzM{G3Ny=>
MDA-MB-231 NHnpSZZHfW6ldHnvckBCe3OjeR?= Mn74NQKBmzRyMDDuUS=> Mn7YOEBp M1PLe5N2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFzIXWwzOjlyNkK1PS=>
MDA-MB-231 M4rEbmZ2dmO2aX;uJGF{e2G7 NVfO[ZppPDByIH7N MVK0JIg> M4THU4Rm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYiyNlkxPjJ3OR?=
Jurkat M{LKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXewMlI2NTFwMkWg{txO NFnYVpMzPC92ODDo M4Xs[2ROW09? NHuxVYtqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= M4nBWFE6PzV5MUi1
Namalwa NHPQXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nPeVAvOjVvMT6yOUDPxE1? NEPCW4szPC92ODDo NFLVVJRFVVOR NYGzVohbcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MlzrNVk4PTdzOEW=
Jurkat NV;iSW91SXCxcITvd4l{KEG|c3H5 M1LBTFAvOjVvMT6yOUDPxE1? M4myN|I1NzR6IHi= NWXnTIxsTE2VTx?= MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MXuxPVc2PzF6NR?=
Namalwa MnvuRZBweHSxc3nzJGF{e2G7 MXiwMlI2NTFwMkWg{txO NIq4c4MzPC92ODDo NHjkZVNFVVOR M4m4eIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1jzSFE6PzV5MUi1
K562 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C3R|I1KGh? NEPCZ2VKSzVyPUK1xtExNjF2IH7N M1fPXVE6PjZ{M{[x
SW1990 MU\GeY5kfGmxbjDBd5NigQ>? M4fVTlAvODFvMTFOwG0> MmO5NUBp MXrpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> M4X1cFE6PDZ7MEKw
RT112  MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX3epYyOMLizszN M{POOlI1KGh? MojtSG1UVw>? NUfldXZ2\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? M2LVfVE5Pzh5OEOy
MHG-U1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnKO|d1OTEEoN88US=> MnfCNlQhcA>? Mk\3SG1UVw>? NHLKbpll\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? M17DO|E5Pzh5OEOy
SMMC-7721 MXvBdI9xfG:|aYOgRZN{[Xl? MoXJNlAxyqCwTR?= MmjSNlQhcA>? NET5d5hqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| M2TLWFE4PTV5MUmx
SMMC-7721 NGHZWmdHfW6ldHnvckBCe3OjeR?= NVTlbVc3OjBywrDuUS=> M4TKPVI1KGh? NVz6TmNrfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= MVqxO|U2PzF7MR?=
HeLa Ml7jSpVv[3Srb36gRZN{[Xl? NVz0fGlWOTBywrDuUeKh MXGxJIg> NFfMWoNidHSncoOgeIhmKG2xcoDoc4xw\3lib3[geIhmKHS{YX7z[oVzemmwIILlZ5lkdGmwZzDjc41x[XK2bXXueC=> NEPXdnoyPjh7MEmxOS=>
MRC5VI MnvuSpVv[3Srb36gRZN{[Xl? NU[4NGtqOTJwNTDtUS=> MlTXNE42KGh? NUTKdohRTE2VTx?= NF\iOJJi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NXO2dnROOTZ{MkezPVQ>
AT5BIVA NHi1em1HfW6ldHnvckBCe3OjeR?= NGj0cGMyOi53IH3N MorONE42KGh? NUSxWnFkTE2VTx?= NEPkPYpi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NXv2NW1LOTZ{MkezPVQ>
M059J NIjqR4NHfW6ldHnvckBCe3OjeR?= M3fEb|EzNjVibV2= NEDIeIExNjViaB?= NYjpb4pHTE2VTx?= M4rWV4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NFfON3EyPjJ{N{O5OC=>
HeLa M{HPRWZ2dmO2aX;uJGF{e2G7 NGGzRXMyOi53IH3N MYSwMlUhcA>? M33scmROW09? NY[2bVlH[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NIPkOG8yPjJ{N{O5OC=>
N2a MVvBdI9xfG:|aYOgRZN{[Xl? M4\6VVAvOS1zMDFOwG0> NVLMc4ZnOiCq NVPyZVF6cW6mdXPld{Bl\WO{ZXHz[YQh[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NGfSOFUyPTh2Mke2Oy=>
Jurkat  MYDLbY5ie2ViQYPzZZk> NVjPN|VwUUN3MDDv[kAzPCCwTR?= M134dFE2PjZ2NUG5

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID